GSK-205352

Study Sponsor: GSK

Study Title

A Phase 3b, Controlled, Open-Label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Single Dose of GlaxoSmithKline’s Meningococcal ACWY Conjugate Vaccine (Menveo), Administered to Healthy Individuals 15 through 55 years of age, approximately 4-6 years after primary ACWY vaccination

Medicine or Vaccine (generic name)

GSK3536820A

Sponsor Identification Number

205352

Trial Registry Identification Number(#'s)

NCT02986854 2016-003186-25

Medical Condition

Infections, Meningococcal

Phase

Phase 3

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=205352

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT02986854

Link to study details on EudraCT (if available)

https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-003186-25

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

October 2019